Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pirbuterol
Drug ID BADD_D01781
Description Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Indications and Usage For the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma.
Marketing Status Discontinued
ATC Code R03AC08; R03CC07
DrugBank ID DB01291
KEGG ID D08387
MeSH ID C009118
PubChem ID 4845
TTD Drug ID D0SS4P
NDC Product Code Not Available
Synonyms pirbuterol | pyrbuterol | CP-24,314-1 | Maxair | pirbuterol dihydrochloride | 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride | pirbuterol sulfate | CP 24315-1 | CP-24315-1 | pirbuterol acetate | pirbuterol acetate salt
Chemical Information
Molecular Formula C12H20N2O3
CAS Registry Number 38677-81-5
SMILES CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation19.06.02.001; 17.02.05.012--
Alopecia23.02.02.001--
Anxiety19.06.02.002--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.005--
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Cough22.02.03.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Extrasystoles02.03.02.003--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastrointestinal pain07.01.05.005--
Glossitis07.14.01.001--Not Available
Headache17.14.01.001--
Hyperkinesia17.01.02.008--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.002--
Insomnia19.02.01.002; 17.15.03.002--
Loss of consciousness17.02.04.004--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Muscle spasms15.05.03.004--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
The 1th Page    1 2    Next   Last    Total 2 Pages